

IMMUNOTHERAPY for Advanced Bladder Cancer: *A STEP FORWARD IN PATIENT CARE*

Saturday, 9 December 2017 | 13.00 – 14.00 | Room A, Palexpo | Geneva, Switzerland

Chair

Thomas Powles, MBBS, MRCP, MD
Barts Cancer Institute
Queen Mary University of London
London, United Kingdom

Faculty

Aristotle Bamias, MD, PhD
National and Kapodistrian
University of Athens
Athens, Greece

Yohann Loriot, MD, PhD
Gustave Roussy
Villejuif, France

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.



prIME Oncology designates this live activity for a maximum of *1 AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Agenda

- 13.00 Welcome and introduction
Thomas Powles, MBBS, MRCP, MD
- 13.02 How much do you know about immunotherapy for bladder cancer?
Thomas Powles, MBBS, MRCP, MD
- 13.10 The biological basis for checkpoint inhibition in cancer treatment
Aristotle Bamias, MD, PhD
- 13.22 Q & A
- 13.25 A giant leap in the treatment options for advanced bladder cancer
Yohann Loriot, MD, PhD
- 13.40 Q & A
- 13.45 Interactive case-based panel discussion
- 13.58 Conclusions and prIME Points™
Thomas Powles, MBBS, MRCP, MD
- 14.00 Adjourn

